3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
7
Pain, Postoperative
2
Agnosia
2
Sigmoidal Tumour
1
Pancreatic Neoplasms
1
Neoplasms
1
Musculoskeletal Pain
1
Hypotension
1
Head and Neck Neoplasms
1
Erector Spinae Block Analgesia
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Bradycardia
1
Bites and Stings
1
Abdominal Cancer Surgery
1
Interventions
pembrolizumab
3
enzalutamide
2
blinatumomab
2
abiraterone
2
Stents
2
Neoadjuvant Therapy
2
Immune Checkpoint Inhibitors
2
Cytochrome P-450 Enzyme System
2
soybean oil, phospholipid emulsion
1
durvalumab
1
dostarlimab
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
Surgical Procedures, Operative
1
Surgical Instruments
1
Radiotherapy, Conformal
1
Radiotherapy
1
Passive Cutaneous Anaphylaxis
1
Palliative Care
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Morphine
1
Lidocaine
1
Levobupivacaine
1
Immunotherapy
1
Hydroxyurea
1
Etoposide
1
Etanercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bites and Stings
×
Levobupivacaine
×
Clear all
NCT02121951
2018-04-10
QLB
National Cancer Institute, Egypt
Phase 4
Withdrawn